Universum Therapeutics

Platform-based therapeutics across oncology, infectives and longevity.

[Universum Therapeutics @Universum_Bio]

Project Update #6: Pairing the meta-learner with an uncertainty layer to generalize host-pathogen dynamics across dis... https://t.co/5lAlQ7ik6d #openlabs

[Universum Therapeutics @Universum_Bio]

Project Update #5: The Meta-Learner and Uncertainty Layer https://t.co/hm6DQny3b5 #openlabs

[Universum Therapeutics @Universum_Bio]

Progress update #4: Applying context-aware adapters to evaluate how modulating the host ISC machinery behaves across... https://t.co/p6vcWohVgh #openlabs

[Universum Therapeutics @Universum_Bio]

Progress Update #3: Context-aware Adapters https://t.co/Vya1C7KgTW #openlabs

[Universum Therapeutics @Universum_Bio]

Progress update #2: Applying the The Multiscale Pathway Mapper & Integrator to the Host's Iron-Sulfur Cluster complex... https://t.co/2PmqowaPIm #openlabs

[Universum Therapeutics @Universum_Bio]

Progress update #1: The multiscale pathway mapper & Intergrator https://t.co/jxyWMvmSNe #openlabs

[Universum Therapeutics @Universum_Bio]

The project will serve as an update series to:

[Universum Therapeutics @Universum_Bio]

Modular multi-scale models for computational drug discovery https://t.co/UjayWGqVlH @openlabsbio

[Universum Therapeutics @Universum_Bio]

A Complementary Computational Platform for our Oncology and Infectious Disease Therapeutic Platform Targeting Iron-Related Pathways https://t.co/U6UrtkWJdb #openlabs

[OpenLabs @openlabsbio]

New on OpenLabs: Universum Therapeutics

@Universum_Bio is exploring how disrupting iron use could affect cancer cells and pathogens.

The team’s research focuses on whether blocking two iron-dependent processes together could limit their growth more effectively than blocking either one alone, and whether healthy cells could tolerate the same approach.

Work in cancer biology or infectious disease research? Explore the project and join the discussion ↓

[Universum Therapeutics @Universum_Bio]

Modular multi-scale models for computational drug discovery https://t.co/UjayWGqVlH @openlabsbio

[Universum Therapeutics @Universum_Bio]

We're building a computational platform that walks a drug-discovery program through the full early-stage journey, from "is this target worth pursuing?" to "should we advance this candidate?". Built for preclinical translation and we are excited to share our evolution.

[Universum Therapeutics @Universum_Bio]

Today marks the last day on our research progress series on @openlabsbio feel free to give us a review or upvote.
Progress update #6 (final): Current conclusion and next phase https://t.co/nAFH9yPmau #openlabs @BioProtocolEco @oxMichelangelo

[Universum Therapeutics @Universum_Bio]

Progress update #5: Refinement and redesign https://t.co/5cC4ZSngiF @openlabsbio

[Universum Therapeutics @Universum_Bio]

Progress update #4: First findings https://t.co/tAeDlaJLdP @openlabsbio

[Universum Therapeutics @Universum_Bio]

Progress update #3: Initial implementation and preparation https://t.co/DS30jw8U4n @openlabsbio

[Universum Therapeutics @Universum_Bio]

Progress update #2: Proposed validation plan https://t.co/T1adbjvFho @openlabsbio

[Universum Therapeutics @Universum_Bio]

@oxMichelangelo @BioProtocol @openlabsbio Done https://t.co/lBWS22CnzH

[Universum Therapeutics @Universum_Bio]

We have kicked-off a project on @openlabsbio
Join us for more updates.

[Universum Therapeutics @Universum_Bio]

A Therapeutic Platform Through Inhibition of Fe–S Cluster Biogenesis and Ribonucleotide Reductase for Infectious Diseases and Cancer https://t.co/hUKkz6k7QP #openlabs @BioProtocol @openlabsbio @oxMichelangelo

[Universum Therapeutics @Universum_Bio]

Progress update #1: Existing knowledge and the research gap https://t.co/KVSzKCygm4 #openlabs

[Universum Therapeutics @Universum_Bio]

We have kicked-off a project on @openlabsbio
Join us for more updates.

[Universum Therapeutics @Universum_Bio]

An Infectious Diseases and Cancer Therapeutic Platform Through Inhibition of Fe–S Cluster Biogenesis and Ribonucleotide Reductase https://t.co/Zr87DjVxzP #openlabs

[Universum Therapeutics @Universum_Bio]

An Infectious Diseases and Cancer Therapeutic Platform Through Inhibition of Fe–S Cluster Biogenesis and Ribonucleotide Reductase https://t.co/Zr87DjVxzP #openlabs

[LvlUp Ventures @Lvlupvc]

🚀 Excited to welcome three new companies today to the LvlUp Ventures ecosystem.

Each is tackling a massive market with a unique approach and strong early validation:

🧠 DOSE: AI-powered support for adults and youth with ADHD, focused on in-the-moment intervention, emotional regulation, and productivity rather than just planning tools. Early traction includes 1,300+ coaching sessions completed, 500+ waitlist signups, 90% invite-to-use conversion, and 100% retention after the first session.

🎨 Kreativio: a mobile-first platform that turns text prompts into custom 3D products, connecting AI design with a distributed manufacturing network. Before launch, they've already generated $55K+ in revenue through KreativioLab, completed 1,500+ sales across four channels, built a 450+ person waitlist, and validated both sides of the marketplace.

🧬 Universum Therapeutics: an AI-powered drug discovery platform identifying conserved biological pathways across oncology, infectious disease, and virology. The team has already screened 3,904 covalent fragments, identified 5 tier-1 candidates, and confirmed 2 dual-target hits spanning both human and pathogen biology.

Three very different companies, but all share the same qualities we look for: ambitious founders, technical differentiation, and evidence that customers or partners are already leaning in.

We’re proud to back DOSE, Kreativio, and Universum Therapeutics and look forward to seeing them scale. 🚀

#venturecapital #startups #AI #healthtech #biotech #futureofwork #3dprinting #ADHD #drugdiscovery